Pictured: Michel Sadelain
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Tuesday, December 18, 2012

Memorial Sloan-Kettering researchers have reported a new method that could allow the development of more-specific, cell-based therapies for cancer.

Pictured: Isabelle Rivière and Michel Sadelain
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Monday, July 16, 2012

Memorial Sloan-Kettering’s trial to evaluate a new therapy for patients with beta-thalassemia is the first to receive FDA approval to treat this disease with genetically engineered cells.

Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens
Feature
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, December 28, 2011

Years of innovative research, technology development, and facility expansion at Memorial Sloan-Kettering have led to several new experimental treatments for people with cancer.

Center News

Subscribe to Our E-newsletter

Get the latest information about cancer care.